

# Igor T Gavrilovic

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1966528/publications.pdf>

Version: 2024-02-01

29  
papers

2,805  
citations

394421

19  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

4386  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Brain metastases: epidemiology and pathophysiology. <i>Journal of Neuro-Oncology</i> , 2005, 75, 5-14.   | 2.9 | 816       |
| 2  | Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.   | 9.4 | 302       |
| 3  | Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4570-4574.                        | 1.6 | 287       |
| 4  | R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.   | 1.4 | 267       |
| 5  | Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. <i>Neuro-Oncology</i> , 2015, 17, 116-121.   | 1.2 | 207       |
| 6  | Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3861-3867.                             | 1.6 | 159       |
| 7  | Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.  | 7.0 | 107       |
| 8  | Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.   | 7.0 | 89        |
| 9  | Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. <i>Neuro-Oncology</i> , 2013, 15, 242-250.  | 1.2 | 83        |
| 10 | A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. <i>Neuro-Oncology</i> , 2016, 18, 873-880. | 1.2 | 72        |
| 11 | Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.  | 1.2 | 56        |
| 12 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.   | 2.9 | 55        |
| 13 | Temozolomide or bevacizumab for spinal cord high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 385-389.   | 2.9 | 42        |
| 14 | A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90.  | 2.9 | 40        |
| 15 | Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.              | 1.6 | 39        |
| 16 | Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment. <i>Oncologist</i> , 2012, 17, 274-278.  | 3.7 | 30        |
| 17 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436.  | 3.7 | 29        |
| 18 | Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. <i>Neuro-Oncology</i> , 2016, 18, 735-743.   | 1.2 | 28        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.  | 1.8 | 24        |
| 20 | Clinical Experience of Cerebrospinal Fluidâ€“Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752. | 2.8 | 17        |
| 21 | Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2007, 85, 217-222.   | 2.9 | 15        |
| 22 | Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 145, 57-63.   | 2.9 | 10        |
| 23 | Diagnosis and treatment of primary central nervous system lymphoma. <i>Current Oncology Reports</i> , 2005, 7, 47-54.   | 4.0 | 7         |
| 24 | Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.   | 1.2 | 6         |
| 25 | Primary central nervous system lymphoma. <i>Current Oncology Reports</i> , 2004, 6, 388-395.  | 4.0 | 5         |
| 26 | Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. <i>BMC Cancer</i> , 2022, 22, 60.                                       | 2.6 | 5         |
| 27 | Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. <i>Neuro-Oncology Practice</i> , 2017, 4, 24-28.   | 1.6 | 4         |
| 28 | In Reply. <i>Oncologist</i> , 2013, 18, e18.  | 3.7 | 3         |
| 29 | Pearls: Primary Brain Tumors. <i>Seminars in Neurology</i> , 2010, 30, 005-009.   | 1.4 | 1         |